Preclinical Biology of Recombinant Human Hemoglobin, Rhb1.1
Open Access
- 1 January 1998
- journal article
- review article
- Published by Taylor & Francis in Artificial Cells, Blood Substitutes, and Immobilization Biotechnology
- Vol. 26 (3) , 231-257
- https://doi.org/10.3109/10731199809117456
Abstract
Historically, the development of hemoglobin based oxygen carriers, HBOCs, were confounded by issues related to activation of the complement cascade and other inflammatory processes, renal toxicity, and significant systemic vasoconstriction. However, with shortages in the blood supply, the risk of infectious agent contamination, and delays associated with complete crossmatch as well as transfusion reactions, HBOC development has assumed greater importance. A successful HBOC in addition to having favorable oxygen binding parameters and colloid oncotic properties, must also have a low toxicity profile, be nonimmunogenic, have positive rheologic properties, and have an adequate in vivo half life. In addition, it must also be stable in vivo and not undergo significant oxidation to methemoglobin or release heme or iron in the vasculature. The preclinical studies which have been designed and executed to address these requirements for recombinant human hemoglobin rHb1.1 serve as the focus of this review. Recombinant Hb1.1 represents the first HBOC to enter clinical trials as a recombinant product in distinction to other HBOCs which are derived from bovine or outdated human blood. While currently in phase II clinical trials, the preclinical biology which has increased our understanding of this molecule are the subject of this review.Keywords
This publication has 14 references indexed in Scilit:
- Recombinant Human Hemoglobin Does Not Affect Renal Function in HumansAnesthesiology, 1997
- Structures of a hemoglobin-based blood substitute: insights into the function of allosteric proteinsStructure, 1997
- Use of Recombinant Hemoglobin Solution in Reversing Lethal Hemorrhagic Hypovolemic Oxygen Debt ShockThe Journal of Trauma: Injury, Infection, and Critical Care, 1997
- Effect of recombinant human hemoglobin on human bone marrow progenitor cells: protection and reversal of 3′ -azido-3′ -deoxythymidine-induced toxicityToxicology Letters, 1996
- Effects of recombinant human hemoglobin on opossum sphincter of Oddi motor functionin Vivo andin VitroDigestive Diseases and Sciences, 1996
- The effects of recombinant human hemoglobin on esophageal motor function in humansGastroenterology, 1995
- Recombinant Human Hemoglobin (rHb1.1) Selectively Inhibits Vasorelaxation Elicited by Nitric Oxide Donors in Rabbit Isolated Aortic RingsJournal of Cardiovascular Pharmacology, 1995
- A human recombinant haemoglobin designed for use as a blood substituteNature, 1992
- Hemoglobin presbyterian: β108 (G10) asparagine→lysine. A hemoglobin variant with low oxygen affinityFEBS Letters, 1978
- Esophageal responses to distension and electrical stimulationJournal of Clinical Investigation, 1969